Financial Insecurity Among US Adults With Psoriasis

Brandon Smith, BA; Priya Engel, MPH; Shivali Devjani, MS; Michael R. Collier, BS; Alexander Egeberg, MD, PhD, DMSc; Jashin J. Wu, MD

PRACTICE POINTS

- The economic burden on patients with psoriasis has been rising over time, as the disease impacts many aspects of patients' lives.
- Various sociodemographic groups among patients with psoriasis are financially insecure. Knowing which groups are at higher risk for poor outcomes due to financial insecurity can assist with appropriate treatment regimens.

To the Editor:

Approximately 3% of the US population, or 6.9 million adults, is affected by psoriasis.¹ Psoriasis has a substantial impact on quality of life and is associated with increased health care expenses and medication costs. In 2013, it was reported that the estimated US annual cost—direct, indirect, intangible, and comorbidity costs—of psoriasis for adults was \$112 billion.² We investigated the prevalence and sociodemographic characteristics of

adult psoriasis patients (aged ≥ 20 years) with financial insecurity utilizing the 2009–2014 National Health and Nutrition Examination Survey (NHANES) data.³

We conducted a population-based, cross-sectional study focused on patients 20 years and older with psoriasis from the 2009-2014 NHANES database to evaluate financial insecurity. Financial insecurity was evaluated by 2 outcome variables. The primary outcome variable was assessed by the question "Are you covered by health insurance or some other kind of health care plan (including health insurance obtained through employment or purchased directly as well as government programs like Medicare and Medicaid that provide medical care or help pay medical bills)?"³ Our secondary outcome variable was evaluated by a reported annual household income of less than \$20,000. P values in Table 1 were calculated using Pearson χ^2 tests. In Table 2, multivariate logistic regressions were performed using Stata/MP 17 (StataCorp LLC) to analyze associations between outcome variables and sociodemographic characteristics. Additionally, we controlled for age, race/ethnicity, sex, education, marital status, US citizenship status, and tobacco use.

doi:10.12788/cutis.0845

E18 | CUTIS®

WWW.MDEDGE.COM/DERMATOLOGY

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

Brandon Smith is from Drexel University College of Medicine, Philadelphia, Pennsylvania. Priya Engel is from California University of Science and Medicine, Colton. Shivali Devjani is from SUNY Downstate Health Sciences University College of Medicine, Brooklyn, New York. Michael R. Collier is from USF Health Morsani College of Medicine, Tampa, Florida. Dr. Egeberg is from the Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. Dr. Wu is from the University of Miami Miller School of Medicine, Florida.

Brandon Smith, Priya Engel, Shivali Devjani, and Michael R. Collier report no conflicts of interest. Dr. Egeberg has received research grants, is on the advisory board for, and/or is a speaker for AbbVie; Almirall; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermavant Sciences, Inc; Eli Lilly and Company; Galápagos NV; Horizon Therapeutics; Janssen Pharmaceuticals; Leo Pharma; Mylan; Novartis; Pfizer; Samsung Bioepis; UCB; and Union Therapeutics. Dr. Wu is or has been a consultant, investigator, or speaker for AbbVie; Almirall; Amgen; Arcutis Biotherapeutics; Aristea Therapeutics, Inc; Bausch Health; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermavant Sciences, Inc; Dr. Reddy's Laboratories; Eli Lilly and Company; EPI Health; Galderma; Janssen Pharmaceuticals; LEO Pharma; Mindera; Novartis; Pfizer; Regeneron Pharmaceuticals; Samsung Bioepis; Sanofi Genzyme; Solius; Sun Pharmaceutical Industries Ltd; UCB; and Zerigo Health. Correspondence: Jashin J. Wu, MD, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, RMSB, Room 2023-A, Miami, FL 33136 (jashinwu@gmail.com).

TABLE 1. Financial Insecurity of US Adults Aged \ge 20 years With Psoriasis^a in NHANES 2009-2014 (N=480)

	No health insurance ^b (n=97)		Household income <\$20,000° (n=123)		
Variable	Weighted % ^d (95% CI)	P value ^e	Weighted % ^d (95% Cl)	P value ^e	
Age, y					
20–30	20.2 (11.8-32.4)	20.2 (11.8-32.4) .9		.009 ^f	
31–40	18.5 (10.4-30.7)		14.3 (8.0-24.5)		
41–50	31.2 (20.0-45.1)		17.2 (10.9-25.9)		
51–60	22.4 (11.7-38.7)		23.8 (13.7-37.9)		
>60	7.7 (3.4-16.3)		30.4 (21.4-41.3)		
Race/ethnicity					
Non-Hispanic White	69.4 (57.9-78.9)	69.4 (57.9-78.9) .003 ^f		.03 ^e	
Non-Hispanic Black	10.1 (5.6-17.6)	10.1 (5.6-17.6)		12.4 (7.5-19.7)	
Other Hispanic/Mexican American	14.5 (8.6-23.6)		12.0 (7.4-18.9)		
Other race/multiracial	6.0 (2.7-12.6)		5.2 (2.2-12.0)		
Sex					
Female	55.5 (41.9-68.4)	<.0001 ^f	73.8 (64.4-81.5)	.5	
Male	44.5 (31.6-58.1)		26.2 (18.5-35.6)		
Education					
<9th grade	7.2 (3.9-13.0)	<.001 ^f	10.0 (5.6-17.0)	.002 ^f	
9th–11th grade	12.4 (6.2-23.1)	12.4 (6.2-23.1)		23.2 (15.1-33.9)	
High school graduate	35.2 (23.1-49.4)	35.2 (23.1-49.4)		24.3 (16.6-34.1)	
Some college	34.7 (22.3-49.6)	34.7 (22.3-49.6)		28.3 (17.5-42.3)	
College graduate	10.5 (4.6-22.2)		14.3 (7.6-25.2)		
Marital status					
No	76.4 (64.5-85.2)	<.0001 ^f	83.7 (74.9-89.9)	<.0001 ^f	
Yes	23.6 (14.8-35.5)		16.3 (10.1-25.1)		
US citizenship status					
No	10.0 (5.3-18.0)	.8	4.2 (1.9-8.8)	.02 ^f	
Yes	90.0 (82.0-94.7)		95.8 (91.2-98.1)		

CONTINUED ON NEXT PAGE

WWW.MDEDGE.COM/DERMATOLOGY

VOL. 112 NO. 2 | AUGUST 2023 E19

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

TABLE 1. (continued)

	No health insurance ^b (n=97)		Household income <\$20,000° (n=123)	
Variable	Weighted %d (95% CI)	P value ^e	Weighted %d (95% CI)	P value ^e
Tobacco use ⁹				
No	33.2 (22.3-46.4)	.9	43.3 (32.1-55.2)	.1
Yes	66.8 (53.6-77.7)		56.7 (44.8-67.9)	

Abbreviation: NHANES, National Health and Nutrition Examination Survey.

^aPsoriasis status was assessed by the question "Have you ever been told by a doctor or other health care professional that you had psoriasis?" ^bInsurance status was assessed by the question "Are you covered by health insurance or some other kind of health care plan (including health insurance obtained through employment or purchased directly as well as government programs like Medicare and Medicaid that provide medical care or help pay medical bills)?"

^cAnnual household income.

^dWeighted percentage was calculated using NHANES survey design parameters.

 ^{e}P values were obtained utilizing Pearson χ^2 test.

^fStatistically significant (2-sided P<.05).

"Tobacco use was assessed by the question "Have you smoked at least 100 cigarettes in your entire life?"

TABLE 2. Multivariate Logistic Regression of Financial Insecurity Among US Adults With Psoriasis^a

Variable No health insurance ^b Household income $<$20,000^{\circ}$ No health insurance ^b No health insurance ^b Age, y 20–30 1.00 (reference) 1.00 (reference) Sex $31-40$ 1.24 (0.44-3.54) 1.59 (0.47-5.37) Male 1.01 (0.51-2.01) $41-50$ 2.63 (0.91-7.59) 1.61 (0.58-4.42) Education Education $51-60$ 0.77 (0.24-2.44) 1.70 (0.55-5.20) 9th grade 1.00 (reference) >60 0.21 (0.07-0.64) ^d 1.57 (0.63-3.91) Education Sex Race/ethnicity Non-Hispanic 1.00 (reference) 1.00 (reference) 9th-11th 0.85 (0.21-3.37) Mite 1.00 (reference) 1.00 (reference) 9th-11th 0.85 (0.21-3.37) Mon-Hispanic 1.69 (0.68-4.22) 2.26 (1.09-4.71) ^d Some college 1.12 (0.31-4.00) College 0.23 (0.06-0.82) ^d graduate Some college 0.23 (0.06-0.82) ^d		AOR (95% CI)			AOR	
Age, ySex $20-30$ 1.00 (reference)1.00 (reference) $31-40$ 1.24 (0.44-3.54)1.59 (0.47-5.37) $41-50$ 2.63 (0.91-7.59)1.61 (0.58-4.42) $51-60$ 0.77 (0.24-2.44)1.70 (0.55-5.20)>600.21 (0.07-0.64) ^d 1.57 (0.63-3.91)Race/ethnicityNon-Hispanic1.00 (reference)Non-Hispanic1.00 (reference)Non-Hispanic1.69 (0.68-4.22)2.26 (1.09-4.71) ^d Black0.169 (0.62-3.88)1.76 (0.76-4.05)Other Hispanic/1.56 (0.62-3.88)1.76 (0.76-4.05)Mexican American0.86 (0.25-2.05)0.80 (0.27-2.94)	Variable	No health insurance ^b	Household income <\$20,000°	Variable	No health insurance ^b	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Age, y			Sex		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	20–30	1.00 (reference)	1.00 (reference)	Female	1.00 (reference)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	31–40	1.24 (0.44-3.54)	1.59 (0.47-5.37)	Male	1.01 (0.51-2.01)	
51-60 0.77 (0.24-2.44) 1.70 (0.55-5.20) >60 0.21 (0.07-0.64) ^d 1.57 (0.63-3.91) Race/ethnicity 9th-11th 0.85 (0.21-3.37) grade High school 1.67 (0.47-6.02) White 1.00 (reference) 1.00 (reference) Non-Hispanic 1.69 (0.68-4.22) 2.26 (1.09-4.71) ^d Black 0.156 (0.62-3.88) 1.76 (0.76-4.05) Mexican American 0.88 (0.25-2.94)	41–50	2.63 (0.91-7.59)	1.61 (0.58-4.42)	Education		
>60 0.21 (0.07-0.64) ^d 1.57 (0.63-3.91) Race/ethnicity 9th-11th 0.85 (0.21-3.37) grade High school 1.67 (0.47-6.02) White 1.00 (reference) 1.00 (reference) Non-Hispanic 1.69 (0.68-4.22) 2.26 (1.09-4.71) ^d Black 0.156 (0.62-3.88) 1.76 (0.76-4.05) Mexican American	51–60	0.77 (0.24-2.44)	1.70 (0.55-5.20)	<9th grade	1.00 (reference)	
Race/ethnicity High school 1.67 (0.47-6.02) White High school 1.67 (0.47-6.02) Non-Hispanic 1.69 (0.68-4.22) 2.26 (1.09-4.71) ^d Black Some college 1.12 (0.31-4.00) Other Hispanic/ 1.56 (0.62-3.88) 1.76 (0.76-4.05) Mexican American 0.89 (0.27-2.94)	>60	0.21 (0.07-0.64) ^d	1.57 (0.63-3.91)	9th–11th grade	0.85 (0.21-3.37)	
Write Some college 1.12 (0.31-4.00) Non-Hispanic 1.69 (0.68-4.22) 2.26 (1.09-4.71) ^d College 0.23 (0.06-0.82) ^d Black	Race/ethnicity Non-Hispanic	1.00 (reference)	1.00 (reference)	High school graduate	1.67 (0.47-6.02)	
Non-Hispanic 1.69 (0.68-4.22) 2.26 (1.09-4.71)° Black College 0.23 (0.06-0.82)° Other Hispanic/ 1.56 (0.62-3.88) 1.76 (0.76-4.05) Mexican American Other race/ 0.86 (0.25-3.95) 0.89 (0.27-3.94)		1 00 (0 00 4 00)	0.00 (1.00 4.71)d	Some college	1.12 (0.31-4.00)	
Other Hispanic/ 1.56 (0.62-3.88) 1.76 (0.76-4.05) graduate Mexican	Black	1.69 (0.68-4.22)	2.26 (1.09-4.71) ^a	College	0.23 (0.06-0.82) ^d	
Other record = 0.86 (0.25, 2.05) = 0.80 (0.27, 2.04)	Other Hispanic/ Mexican American	1.56 (0.62-3.88)	1.76 (0.76-4.05)	graduate		
multiracial	Other race/ multiracial	0.86 (0.25-2.95)	0.89 (0.27-2.94)			

E20 I CUTIS®

WWW.MDEDGE.COM/DERMATOLOGY

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

TABLE 2. (continued)

	AOR (95% CI)		
Variable	No health insurance ^b	Household income <\$20,000°	
Marital status			
No	1.00 (reference)	1.00 (reference)	
Yes	0.18 (0.08-0.38) ^d	0.14 (0.07-0.27) ^d	
US citizenship status			
No	1.00 (reference)	1.00 (reference)	
Yes	0.19 (0.05-0.73) ^d	5.01 (1.28-19.63) ^d	
Tobacco use ^e			
No	1.00 (reference)	1.00 (reference)	
Yes	2.02 (1.00-4.05) ^d	0.95 (0.51-1.76)	

Abbreviation: AOR, adjusted odds ratio.

^aPsoriasis status was assessed by the question "Have you ever been told by a doctor or other health care professional that you had psoriasis?"

^bInsurance status was assessed by the question "Are you covered by health insurance or some other kind of health care plan (including health insurance obtained through employment or purchased directly as well as government programs like Medicare and Medicaid that provide medical care or help pay medical bills)?"

^cAnnual household income.

^dStatistically significant (2-sided P<.05).

^eTobacco use was assessed by the question "Have you smoked at least 100 cigarettes in your entire life?"

Subsequently, relationships with P<.05 were considered statistically significant.

Our analysis comprised 480 individuals with psoriasis; 40 individuals were excluded from our analysis because they did not report annual household income and health insurance status (Table 1). Among the 480 individuals with psoriasis, approximately 16% (weighted) reported a lack of health insurance, and approximately 17% (weighted) reported an annual household income of less than \$20,000. Among those who reported an annual household income of less than \$20,000, approximately 38% (weighted) of them reported that they did not have health insurance.

Multivariate logistic regression analyses revealed that elderly individuals (aged >60 years), college graduates, married individuals, and US citizens had decreased odds of lacking health insurance (Table 2). Additionally, those with a history of tobacco use (adjusted odds ratio [AOR] 2.02; 95% CI, 1.00-4.05) were associated with lacking health insurance. Non-Hispanic Black individuals (AOR 2.26; 95% CI, 1.09-4.71) and US citizens (AOR 5.01; 95% CI, 1.28-19.63) had a significant association with an annual household income of less than \$20,000 (P<.05). Lastly, males, those with education beyond ninth grade, and married individuals had a significantly decreased odds of having an annual household income of less than \$20,000 (P<.05)(Table 2).

Our findings indicate that certain sociodemographic groups of psoriasis patients have an increased risk for being financially insecure. It is important to evaluate the cost of treatment, number of necessary visits to the office, and cost of transportation, as these factors can serve as a major economic burden to patients being managed for psoriasis.⁴ Additionally, the cost of biologics has been increasing over time.⁵ Taking all of this into account when caring for psoriasis patients is crucial, as understanding the financial status of patients can assist with determining appropriate individualized treatment regimens.

REFERENCES

- Liu J, Thatiparthi A, Martin A, et al. Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys. J Am Acad Dermatol. 2021;84:767-769. doi:10.1016/j.jaad.2020.10.035
- Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151:651-658. doi:10.1001/jamadermatol.2014.3593
- National Center for Health Statistics. NHANES questionnaires, datasets, and related documentation. Centers for Disease Control and Prevention website. Accessed June 22, 2023. https://wwwn .cdc.govnchs/nhanes/Default.aspx
- Maya-Rico AM, Londoño-García Á, Palacios-Barahona AU, et al. Out-of-pocket costs for patients with psoriasis in an outpatient dermatology referral service. An Bras Dermatol. 2021;96:295-300. doi:10.1016/j.abd.2020.09.004
- Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context. 2014;3:212266. doi:10.7573/dic.212266

WWW.MDEDGE.COM/DERMATOLOGY

VOL. 112 NO. 2 | AUGUST 2023 E21

Copyright Cutis 2023. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.